Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.
तुलना करने के लिए मीट्रिक्स | TYP | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधTYPपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −7.6x | −5.8x | −0.5x | |
PEG अनुपात | −0.54 | −0.02 | 0.00 | |
क़ीमत/बुक | - | 4.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 42.3x | 14.0x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 277.4% | 51.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | −1.5% | 9.5% | अनलॉक करें |